Blocking LAG-3 activity and anti-PD-1 or PD-L1 in tumor cells has dual inhibitory effects, including inhibiting Treg activity, promoting DC maturation, and rescuing dysfunctional CD4+/CD8+ T cells (60). This evidence concerns the gene CD274 and neoplasm.